PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer
PR94004
BOSTON, Jan. 12, 2022 /PRNewswire=KYODO JBN/ --
PostEra, a biotechnology company specializing in machine learning for
preclinical drug discovery, today announced the expansion of the company's
existing strategic collaboration (
) with Pfizer. The expanded multi-target research program will establish an AI
Lab where PostEra and Pfizer jointly advance multiple drug discovery programs
with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI
Lab will leverage novel machine learning for medicinal chemistry built upon
Pfizer's data, and PostEra's pioneering innovations in generative chemistry and
synthesis-aware design.
Logo - https://mma.prnewswire.com/media/1722598/PostEra_Logo.jpg
PostEra will receive an upfront payment of $13M and is eligible to receive
additional milestone payments totalling up to $248M should all milestones be
achieved, in addition to tiered royalties on any approved products arising out
of the collaboration.
The AI Lab will tightly integrate drug discovery with technology development to
ensure a continuous feedback loop that refines both the process and predictions
from the platform. The vision of the AI Lab is to combine Pfizer's expertise
and data with PostEra's technology to advance these drug discovery programs,
while also producing an integrated state-of-the-art platform to be deployed
across Pfizer's in-house, preclinical drug discovery efforts.
"We think the best way to build leading technology is to have its development
tightly integrated with live drug discovery programs", said Dr. Alpha Lee,
Chief Scientific Officer of PostEra. "We're pleased that we are expanding the
existing collaboration to do exactly this and to reap the AI advantage in
improving preclinical drug discovery," added Aaron Morris, CEO of PostEra.
"At Pfizer, we believe digital technologies, including artificial intelligence
and machine learning, hold great potential to aid the discovery of novel
approaches to prevent, cure, and treat disease for patients in need," said
Charlotte Allerton, Head of Medicine Design, Pfizer. "We're excited to extend
our collaboration with PostEra to further build on our current capabilities."
The company today also announced its $24M Series A financing. The new funding
will enable PostEra to further expand its partnered drug discovery programs,
initiate internal drug discovery programs, as well as further develop its
AI-first medicinal chemistry platform.
About PostEra
PostEra was founded in 2019 and its technology is built on pioneering academic
research done by its founding scientists. PostEra's technology addresses some
of the key challenges in drug discovery R&D by integrating molecular design
with chemical synthesis. PostEra advances small molecule programs through
partnerships with biopharma, working on its own internal pipeline, and also
offering some of its synthesis technology via its Manifold (
) web platform. PostEra also launched and now helps lead the world's largest
open-science drug discovery effort; COVID Moonshot (
).
SOURCE: PostEra
CONTACT: Aaron Morris, Chief Executive Officer, E-mail: founders@postera.ai
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
